PureTech Health plc (LSE: PRTC), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced a new corporate headquarters and labs in Boston’s Seaport District.
The state-of-the-art, integrated office and laboratory space will support the Company’s plans to expand and accelerate development of its internal R&D pipeline, which is centred on lymphatic targeting and tissue-selective immunomodulation for the potential treatment of immune and central nervous system disorders, lymphatic conditions, and cancers.
“The PureTech team has initiated and advanced highly differentiated product candidates initially targeting serious disorders of the brain, immune system, and gastrointestinal tract, and has progressed more than two dozen product candidates from discovery through various points of validation, including one all the way through FDA regulatory clearance. It is through this track record of execution that we have built our leadership position around brain-immune-gut “BIG” axis biology and identified the platforms that form the basis of our internal R&D pipeline programs,” said founder and CEO Daphne Zohar. “PureTech’s expanded presence in the world’s premier biotech and biopharmaceutical R&D ecosystem reflects our commitment to leveraging this unique expertise around the BIG axis with the goal of bringing transformational new medicines to patients.”
PureTech’s internal R&D pipeline includes several programs that harness the lymphatic system, which plays a crucial role in programming immune cells for precise functions and trafficking them to specific tissues. These programs include proprietary lymphatic-targeting platforms leveraging milk derived exosomes and lipid cloaking technologies, as well as approaches to modulate lymphatic flow and vessel dysfunction. PureTech has entered into research collaborations with two major pharmaceutical companies leveraging two of these platforms with partners’ specific product candidates or modalities during the past 12 months.
PureTech is also advancing two, first-in-class, fully-human monoclonal antibodies (mAbs) targeting Galectin-9 (LYT-200) and immunosuppressive γδ1 (gamma delta) T cells (LYT-210) for the treatment of cancers that currently do not respond or respond poorly to approved immunotherapies. These unique mAbs target foundational mechanisms of tumoral immune escape and immunosuppression and have been tested as single agents as well as in combination with anti-PD1 in a variety of preclinical murine and human-derived ex vivo models. As such, PureTech believes they represent novel additions to the armamentarium of immuno-oncology agents, with potential application across multiple solid tumours, including malignancies that historically have proved difficult to treat. PureTech expects to file an investigational new drug (IND) application for its lead immuno-oncology program, LYT-200, in the first half of 2020.
“Tissue-selective, rather than systemic, immunomodulation is a powerful new avenue for more tailored medicines, and cutting-edge research is validating the lymphatic system as an important highway for immune activity across countless conditions,” said chief scientific officer Joe Bolen, PhD. “At PureTech, we are proud to have built a world-class team of researchers, collaborators, and advisers around these areas to advance our scientific vision. The consolidation and colocation of our formerly Cambridge- and Boston-based labs into this new state-of-the-art facility will support the continued expansion and rapid advancement of this vision as we build out our internal pipeline.”
PureTech’s new offices and labs are located at 6 Tide Street in Boston. The Company’s facility in the Back Bay neighbourhood of Boston will continue to house several of its affiliates.